Inotiv (NOTV) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
8 Jul, 2026Executive summary
Achieved strong year-over-year revenue growth in Q4 and full year 2025, driven by the Discovery and Safety Assessment (DSA) segment.
Q4 FY 2025 revenue rose 5.9% year-over-year to $138.1 million, with full-year revenue up 4.5% to $513.0 million.
Q4 operating loss decreased 48.5% to $6.8 million; full-year operating loss down 64.2% to $30.9 million.
Adjusted EBITDA for Q4 2025: $11.8M (8.5% margin); full year: $34M (6.6% margin), both up significantly from prior year.
Managed a cybersecurity incident in Q4 with minimal disruption to operations and maintained business momentum.
Financial highlights
FY 2025 net loss was $68.6 million (13.4% of revenue), improved from $108.9 million (22.2%) in FY 2024.
Net loss attributable to common shareholders in Q4 2025: $8.6M ($0.25/share), improved from $18.9M loss ($0.73/share) in Q4 2024.
Cash and cash equivalents at year-end were $21.7 million; total debt was $402.1 million.
Capital expenditures for FY 2025 totaled $16.6 million (3.2% of revenue), down from $22.3 million in FY 2024.
DSA Q4 revenue increased 15.7% year-over-year; DSA awards up 61% year-over-year.
Outlook and guidance
Not providing formal fiscal 2026 guidance due to market and tariff uncertainties.
Management remains optimistic about continued DSA growth and margin improvement, with positive trends in quoting and awards in the first two months of the new fiscal year.
Management remains focused on improving cash flow, margins, and client metrics, with continued execution of strategic plans.
DSA net awards increased approximately 61% year-over-year in Q4, supporting future growth.
Q1 is typically the weakest quarter due to holiday seasonality.
Latest events from Inotiv
- Improved bookings, margin recovery, and proactive risk management drive positive outlook.NOTV
Jefferies Global Healthcare Conference 20258 Jul 2026 - Strong DSA growth and operational improvements drive performance amid stable RMS and evolving market dynamics.NOTV
Baird Global Healthcare Conference 20258 Jul 2026 - Net loss widened to $32.5M on a 5.4% revenue decline, with significant going concern risks.NOTV
Q2 202611 May 2026 - Q1 2026 revenue hit $120.9M as efficiency, site optimization, and compliance drive growth.NOTV
Investor presentation9 Feb 2026 - Revenue up 0.8% with DSA growth, but net loss and liquidity risks persist.NOTV
Q1 20269 Feb 2026 - Q3 revenue fell 32.8% with a $26.1M loss; legal issues resolved but liquidity risks remain.NOTV
Q3 20242 Feb 2026 - New services and capacity drive DSA growth, while NHP and small animal markets adjust to shifting demand.NOTV
Jefferies Global Healthcare Conference1 Feb 2026 - FY 2024 revenue fell 14.3% with margin pressure, but operational changes target recovery in 2025.NOTV
Q4 202412 Jan 2026 - Operational optimization and DSA growth drive revenue and margin expansion.NOTV
H.C. Wainwright 27th Annual Global Investment Conference27 Dec 2025